SELLAS Life Sciences (NASDAQ: SLS) raises $42.6M via warrant exercises

Rhea-AI Filing Summary

SELLAS Life Sciences Group, Inc. reports it has received approximately $42.6 million in cash proceeds from the exercise of common stock warrants subsequent to December 31, 2025. This total includes about $26.5 million received by January 8, 2026 and an additional $16.1 million received after that date.

As of March 11, 2026, the company had 179,536,724 shares of common stock outstanding. The update highlights recent warrant exercises that brought in cash and increased the number of shares held by investors exercising those warrants.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001390478 0001390478 2026-03-11 2026-03-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 11, 2026

SELLAS Life Sciences Group, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-33958		20-8099512
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)
		7 Times Square, Suite 2503 New York, NY 10036
		(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (646) 200-5278

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	SLS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events

As previously reported on January 8, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) received approximately $26.5 million in proceeds as of such date from the exercise of common stock warrants subsequent to December 31, 2025. Since January 8, 2026, the Company received approximately $16.1 million in proceeds from the exercise of additional common stock warrants for a total of approximately $42.6 million in proceeds subsequent to December 31, 2025.

As of March 11, 2026, the Company had 179,536,724 shares of common stock outstanding.

2

Item 9.01. Financial Statements and Exhibits.

(d)       Exhibits

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SELLAS Life Sciences Group, Inc.
Date:	March 11, 2026	By:	/s/ John T. Burns
			Name:	John T. Burns
			Title:	Senior Vice President, Chief Financial Officer

4

FAQ

What cash proceeds did SELLAS Life Sciences (SLS) receive from warrant exercises?

SELLAS Life Sciences received approximately $42.6 million in cash from common stock warrant exercises after December 31, 2025. This reflects investors converting warrants into shares, providing the company with additional funds while increasing its outstanding common stock base.

How much of SELLAS Life Sciences’ (SLS) warrant proceeds were received by January 8, 2026?

By January 8, 2026, SELLAS Life Sciences had received about $26.5 million in proceeds from warrant exercises. These exercises occurred after December 31, 2025 and represent the first portion of the total cash inflow disclosed in this update.

What additional warrant exercise proceeds did SELLAS Life Sciences (SLS) report after January 8, 2026?

After January 8, 2026, SELLAS Life Sciences received approximately $16.1 million more from additional common stock warrant exercises. Together with earlier exercises, this brought total proceeds since December 31, 2025 to about $42.6 million, strengthening the company’s cash position.

How many SELLAS Life Sciences (SLS) shares were outstanding as of March 11, 2026?

As of March 11, 2026, SELLAS Life Sciences had 179,536,724 shares of common stock outstanding. This figure reflects the share count after the reported warrant exercises that generated approximately $42.6 million in proceeds for the company.

What event prompted SELLAS Life Sciences (SLS) to file this 8-K update?

The update was prompted by SELLAS Life Sciences receiving approximately $42.6 million in total proceeds from common stock warrant exercises after December 31, 2025. The company also disclosed its updated outstanding share count as of March 11, 2026.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.9 KB